[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575668":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":43,"centralContacts":47,"locations":52,"responsibleParty":74,"collaborators":26,"id":76,"slug":77,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":26,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":26,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":26,"overallStatus":55,"whyStopped":26,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"The First Affiliated Hospital of Guangzhou Medical University","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"four-drug combination group","EXPERIMENTAL","PD-L1 inhibitor with chemotherapy with Antiangiogenic therapy for neoadjuvant therapy",[13,14,15],"Drug: Adebellizumab","Drug: Bevacizumab","Drug: Platinum-based chemotherapy",{"label":17,"type":10,"description":18,"interventionNames":19},"three-drug combination group","PD-L1 inhibitor with chemotherapy for neoadjuvant therapy",[13,15],[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Adebellizumab","adebrelimab",[9,17],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Bevacizumab","bevacizumab",[9],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Platinum-based chemotherapy","paclitaxel or albuminotaxol or docetaxel combined with platinum, pemetrexed combined with platinum. Platinums include carboplatin, cisplatin and nedaplatin.",[9,17],[36,37,38,39,40,41,42],"paclitaxel","albuminotaxol","docetaxel","pemetrexed","carboplatin","cisplatin","nedaplatin",[44],{"name":45,"affiliation":5,"role":46},"Jianxing He","PRINCIPAL_INVESTIGATOR",[48],{"name":45,"role":49,"phone":50,"phoneExt":26,"email":51},"CONTACT","+86-20-83062807","jianxing.he@gmail.com",[53],{"facility":54,"status":55,"city":56,"state":26,"zip":26,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University","RECRUITING","Guangzhou","China","CN",{"type":60,"coordinates":61},"Point",[62,63],113.25,23.11667,{"lat":63,"lon":62},[66,68,72,73],{"name":67,"role":49,"phone":50,"phoneExt":26,"email":51},"Jianxing He, MD",{"name":69,"role":49,"phone":70,"phoneExt":26,"email":71},"Wenhua Liang, MD","+86-13710249454","550627660@qq.com",{"name":67,"role":49,"phone":26,"phoneExt":26,"email":26},{"name":69,"role":49,"phone":26,"phoneExt":26,"email":26},{"type":46,"investigatorFullName":45,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Director","100575668","phase-2-a-study-of-adebrelimab-in-combination-with-chemo-with-or-without-bevacizumab-neoadjuvant-therapy-for-resectable-nsclc-100575668",false,"NCT06775275","A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC","A Randomized Phase II Study of Adebrelimab in Combination with Chemotherapy with or Without Bevacizumab Neoadjuvant Therapy for Resectable Non-Squamous Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Resectable NSQ NSCLC\n* Age 18-65 years\n* male or female\n* ECOG 0-1\n* Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer\n* Subjects must have adequate pulmonary function for the intended pneumonectomy;\n\nExclusion Criteria:\n\n* SCLC or SQ NSCLC\n* previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.\n* patients who have previously used anti-angiogenic drugs;\n* allergic to any component of the study drug or chemotherapy drugs\n* patients with any severe and or uncontrolled disease","ALL","18 Years","65 Years",{"count":87,"type":88},60,"ESTIMATED","INTERVENTIONAL",[91],"PHASE2","This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.",[94],"Resectable Lung Non-Small Cell Carcinoma","2025-01-09",{"date":97,"type":98},"2025-01-15","ACTUAL",{"date":100,"type":98},"2024-09-24",{"date":102,"type":88},"2029-12-31",{"name":5,"class":6},1]